Valeo Pharma Past Earnings Performance
Past criteria checks 0/6
Valeo Pharma's earnings have been declining at an average annual rate of -41.9%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 48% per year.
Key information
-41.9%
Earnings growth rate
-34.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 48.0% |
| Return on equity | n/a |
| Net Margin | -60.2% |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Valeo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 53 | -32 | 28 | 0 |
| 30 Apr 24 | 55 | -30 | 30 | 0 |
| 31 Jan 24 | 54 | -28 | 30 | 0 |
| 31 Oct 23 | 54 | -28 | 30 | 0 |
| 31 Jul 23 | 53 | -28 | 28 | 0 |
| 30 Apr 23 | 45 | -27 | 28 | 0 |
| 31 Jan 23 | 37 | -26 | 27 | 0 |
| 31 Oct 22 | 28 | -26 | 26 | 0 |
| 31 Jul 22 | 18 | -24 | 25 | 0 |
| 30 Apr 22 | 18 | -22 | 23 | 0 |
| 31 Jan 22 | 16 | -18 | 20 | 0 |
| 31 Oct 21 | 14 | -14 | 16 | 0 |
| 31 Jul 21 | 12 | -9 | 10 | 0 |
| 30 Apr 21 | 8 | -7 | 7 | 0 |
| 31 Jan 21 | 8 | -5 | 6 | 0 |
| 31 Oct 20 | 7 | -5 | 6 | 0 |
| 31 Jul 20 | 7 | -4 | 6 | 0 |
| 30 Apr 20 | 8 | -2 | 5 | 0 |
| 31 Jan 20 | 6 | -4 | 5 | 0 |
| 31 Oct 19 | 7 | -4 | 5 | 0 |
| 31 Jul 19 | 7 | -3 | 5 | 0 |
| 30 Apr 19 | 7 | -3 | 4 | 0 |
| 31 Jan 19 | 6 | -3 | 4 | 0 |
| 31 Oct 18 | 4 | -2 | 3 | 0 |
| 31 Jul 18 | 3 | -3 | 3 | 0 |
| 31 Oct 17 | 1 | -4 | 3 | 0 |
| 31 Oct 16 | 1 | -1 | 3 | 0 |
Quality Earnings: VP2 is currently unprofitable.
Growing Profit Margin: VP2 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VP2 is unprofitable, and losses have increased over the past 5 years at a rate of 41.9% per year.
Accelerating Growth: Unable to compare VP2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VP2 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: VP2's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.